medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-19-50-55medsovet-2746Research ArticleХимиотерапия злокачественных опухолейMalignant tumor chemotherapyФармакоэкономическая оценка применения таргетной терапии и химиотерапии в первой и второй линиях лечения метастатического колоректального ракаPharmacoeconomic evaluation of the use of targeted therapy and chemotherapy in the first- and second-line therapies for metastatic colorectal cancerТрякинА. А.TryakinA. A.

д.м.н., отделение клинической фармакологии и химиотерапии ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России, Научно-исследовательский институт онкологии Башкирского государственного медицинского университета

БалуновП. А.BalunovP. A.

медицинский редактор

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияBlokhin Russian Cancer Research Center of the Ministry of Health of RussiaRussian FederationООО «ГРУППА КОМПАНИЙ «РЕМЕДИУМ»РоссияREMEDIUM GROUP LtdRussian Federation2018111120180195055Copyright © Трякин А.А., Балунов П.А., 20182018Трякин А.А., Балунов П.А.Tryakin A.A., Balunov P.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2746

Колоректальный рак (КРР) – генетически гетерогенное заболевание, при котором прогноз и эффективность лечения определяются локализацией первичной опухоли (лево- и правосторонняя). КРР занимает верхние строчки по распространенности в РФ, четверть диагнозов ставится на IV стадии. Выбор наиболее оптимальной схемы терапии – актуальный вопрос для современного онколога, имеющего в арсенале проверенные временем эффективные комбинации химиотерапии и современные таргетные препараты. Цель данной работы – фармакоэкономический обзор с учетом как клинических, так и экономических параметров того или иного варианта фармакотерапии КРР. В итоге установлено, что применение химиотерапевтических схем в первой и второй линиях терапии пациентов с КРР является наиболее фармакоэкономически обоснованным по сравнению с применением таргетной терапии на начальном этапе.

Colorectal cancer (CRC) is a genetically heterogeneous disease, which prognosis and efficacy of treatment are determined by the localization of the primary tumour (left- and right-sided tumours). CRC ranks high in prevalence in the Russian Federation, a quarter of cases are diagnosed at stage IV. The choice of the most optimal therapy regimen is a topical issue for a modern oncologist, who has time-proven combinations of chemotherapy and modern targeted drugs in the arsenal. The aim of this article is to provide a pharmacoeconomic review, taking into account both clinical and economic parameters of one or another CRC pharmacotherapy regimen. As a result, it was found that the use of chemotherapeutic regimens in the first- and second-line therapies of patients with CRC is the most pharmacoeconomically justified as compared with the use of targeted therapy at the initial stage.

колоректальный ракфармакоэкономикахимиотерапиятаргетная терапияcolorectal cancerpharmacoeconomicschemotherapytargeted therapyReferencesLindsey A. Torre MSPH. Global cancer statistics, 2012. CA Cancer J Clin, 2015 March/April, 65(2): 87–108.Lindsey A. Torre MSPH. Global cancer statistics, 2012. CA Cancer J Clin, 2015 March/April, 65(2): 87–108.Каприн А.Д., Старинский В.В. Злокачест венные новообразования в России в 2017 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.Kaprin AD, Starinsky VV. Malignant neoplasms in Russia in 2017. M.: Hertsen Moscow Oncology Research Center – a branch of the Federal Research Center of Radiology of the Ministry of Health of Russia, 2018.Федоров В.Э., Поделякин К.А. Эпидемиологические аспекты колоректального рака (обзор). Медицинский альманах, 2017 сентябрь, 4(49):145-148.Fedorov VE, Podelyakin KA. Epidemiological aspects of colorectal cancer (review). Meditsinskiy Almanakh, 2017 September, 4 (49): 145-148Arnold D, Lueza B, Douillard J-Y, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Annals of Oncology. Published online 12 April 2017.Arnold D, Lueza B, Douillard J-Y, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Annals of Oncology. Published online 12 April 2017.Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 2004, 22: 1209-1214.Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 2004, 22: 1209-1214.Venook AP, Niedzwiecki D, Innocenti F et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mcrc): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol, 2016, 34(suppl.): abstr. 3504.Venook AP, Niedzwiecki D, Innocenti F et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mcrc): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol, 2016, 34(suppl.): abstr. 3504.Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 2008, 26: 374-379.Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 2008, 26: 374-379.Douillard JY, Oliner KS, Siena S et al. Panitumu mabFOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med, 2013, 369: 1023-1034.Douillard JY, Oliner KS, Siena S et al. Panitumu mabFOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med, 2013, 369: 1023-1034.Федянин М.Ю. Современная клиническая и молекулярно-биологическая платформа лечения больных раком толстой кишки. Диссертация. М., 2017.Fedyanin MYu. Modern clinical and molecular biological platform for the treatment of patients with colon cancer. Dissertation. M., 2017.Douillard JY. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 2010 Nov 1, 28(31): 4697-4705.Douillard JY. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 2010 Nov 1, 28(31): 4697-4705.Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G,Siena S, Tabernero J, Douillard J-Y, André T, Peeters M. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Annals of Oncology, 2017 August 1, 28(Issue 8): 1862–1868.Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G,Siena S, Tabernero J, Douillard J-Y, André T, Peeters M. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Annals of Oncology, 2017 August 1, 28(Issue 8): 1862–1868.Tejpar S. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol, 2016 Oct 10.Tejpar S. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol, 2016 Oct 10.Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol, 2011, 29: 2011– 2019.Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol, 2011, 29: 2011– 2019.Loupakis F, Yang D, Yau L et al. Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. JNCI Journal of the National Cancer Institute, 2015, 107(3): dju427. Doi:10.1093/jnci/dju427.Loupakis F, Yang D, Yau L et al. Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. JNCI Journal of the National Cancer Institute, 2015, 107(3): dju427. Doi:10.1093/jnci/dju427.Cassidy J. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer, 2011 Jun 28, 105(1): 58-64.Cassidy J. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer, 2011 Jun 28, 105(1): 58-64.Giantonio BJ. Bevacizumab in Combination WithOxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology, 2007, 25(12): 1539-1544.Giantonio BJ. Bevacizumab in Combination WithOxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology, 2007, 25(12): 1539-1544.Van Cutsem E. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an OxaliplatinBased Regimen. Journal of Clinical Oncology, 2012, 30(28): 3499-3506.Van Cutsem E. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an OxaliplatinBased Regimen. Journal of Clinical Oncology, 2012, 30(28): 3499-3506.Федянин М.Ю., Алиева Ш.А., Владимирова Л.Ю., Иванов А.Н., Катков А.А. и др. Качество оказания противоопухолевого лечения в популяции больных метастатическим раком толстой кишки в рутинной клинической практике. Злокачественные опухоли. Спецвыпуск 1, 2017, 7(3): 4-11.Fedyanin MYu, Aliyeva ShA, Vladimirova LYu, Ivanov AN, Katkov AA, et al. The quality of antitumor treatment in patients with metastatic colon cancer in routine clinical practice. Zlokachestvennye Opukholi. Special Issue 1, 2017, 7 (3): 4-11.

The authors declare that there are no conflicts of interest present.